ArticleBMC public health2016
Coverage, efficacy or dosing interval: which factor predominantly influences the impact of routine childhood vaccination for the prevention of varicella? A model-based study for Italy.
Article in BMC public health, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 30 citations in OpenAlex.
- Varicella and Zoster Vaccination Strategies in Immunosuppressed Pediatric Transplant Recipients.Vaccines · 2025Review
- Global burden of varicella and herpes zoster across 204 countries, 1990-2021: a temporal trend analysis in the era of the COVID-19 pandemic and projections to 2036.Frontiers in public health · 2025Article
- Impact of natural and socio-economic factors on varicella incidence in children in Shanghai, 2013-2022.Frontiers in public health · 2025Article
- The epidemiology of varicella and effectiveness of varicella vaccine in Ganyu, China: a long-term community surveillance study.BMC public health · 2023Article
- A Dynamic Compartmental Model to Explore the Optimal Strategy of Varicella Vaccination: An Epidemiological Study in Jiangsu Province, China.Tropical medicine and infectious disease · 2022Article
- Evaluating the impact of universal varicella vaccination among preschool-aged children in Qingdao, China: An interrupted time-series analysis.Human vaccines & immunotherapeutics · 2022Article
- Epidemiological Impact and Cost-Effectiveness of Varicella Vaccination Strategies in the United Kingdom.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021Article
- Looking beyond COVID-19 vaccine phase 3 trials.Nature medicine · 2021Review
- Clinical and economic impact of universal varicella vaccination in Norway: A modeling study.PloS one · 2021Article
- Clinical characteristics and risk factors associated with breakthrough varicella during varicella outbreaks.Human vaccines & immunotherapeutics · 2020Article
- Budget impact analysis of multiple varicella vaccination strategies: a Mexico perspective.Human vaccines & immunotherapeutics · 2020Article
- The impact of long-term moderate level of vaccination coverage for epidemiology of varicella in Lu'an, China: should we change immunisation strategy now?Epidemiology and infection · 2020Article
- A persistent outbreak of varicella in a primary school in Dongguan City, Guangdong Province, China.The Journal of international medical research · 2020Article
- The Cost-Effectiveness of Universal Varicella Vaccination in Italy: A Model-Based Assessment of Vaccination Strategies.ClinicoEconomics and outcomes research : CEOR · 2020Article
- Cost-effectiveness analysis of universal varicella vaccination in Turkey using a dynamic transmission model.PloS one · 2019Article
- Varicella zoster virus vaccines: an update.ImmunoTargets and therapy · 2019Article
- Impact of vaccination programs against measles, varicella and meningococcus C in Italy and in Tuscany and public health policies in the last decades.Journal of preventive medicine and hygiene · 2018Article
- Varicella vaccination - the global experience.Expert review of vaccines · 2017Review
- Evaluation of varicella vaccine effectiveness as public health tool for increasing scientific evidence and improving vaccination programs.Jornal de pediatriaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundVaricella is a highly infectious disease with a significant public health and economic burden, which can be prevented with childhood routine varicella vaccination. Vaccination strategies differ by country. Some factors are known to play an important role (number of doses, coverage, dosing interval, efficacy and catch-up programmes), however, their relative impact on the reduction of varicella in the population remains unclear. This paper aims to help policy makers prioritise the critical factors to achieve the most successful vaccination programme with the available budget.
methodsScenarios assessed the impact of different vaccination strategies on reduction of varicella disease in the population. A dynamic transmission model was used and adapted to fit Italian demographics and population mixing patterns. Inputs included coverage, number of doses, dosing intervals, first-dose efficacy and availability of catch-up programmes, based on strategies currently used or likely to be used in different countries. The time horizon was 30 years.
resultsBoth one- and two-dose routine varicella vaccination strategies prevented a comparable number of varicella cases with complications, but two-doses provided broader protection due to prevention of a higher number of milder varicella cases. A catch-up programme in susceptible adolescents aged 10-14 years old reduced varicella cases by 27-43 % in older children, which are often more severe than in younger children. Coverage, for all strategies, sustained at high levels achieved the largest reduction in varicella. In general, a 20 % increase in coverage resulted in a further 27-31 % reduction in varicella cases. When high coverage is reached, the impact of dosing interval and first-dose vaccine efficacy had a relatively lower impact on disease prevention in the population. Compared to the long (11 years) dosing interval, the short (5 months) and medium (5 years) interval schedules reduced varicella cases by a further 5-13 % and 2-5 %, respectively. Similarly, a 10 % increase in first-dose efficacy (from 65 to 75 % efficacy) prevented 2-5 % more varicella cases, suggesting it is the least influential factor when considering routine varicella vaccination.
conclusionsVaccination strategies can be implemented differently in each country depending on their needs, infrastructure and healthcare budget. However, ensuring high coverage remains the critical success factor for significant prevention of varicella when introducing varicella vaccination in the national immunisation programme.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.